🟢 Korro Bio is trading 5% up today after KRRO-111 reduced liver Z-AAT up to 95%

Korro Bio is trading 5.49% up at $9.80 after announcing positive preclinical data for KRRO-111 on October 22, 2026. - In mouse studies, KRRO-111 showed RNA-editing activity. - The candidate reduced pathogenic liver Z-AAT by up to 95%. - The company says KRRO-111 may address both lung and liver manifestations of AATD.